...
首页> 外文期刊>Oncogene >The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants
【24h】

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

机译:Met激酶抑制剂SU11274对不同的受体突变变体表现出选择性抑制模式

获取原文
           

摘要

Point mutations constitute a major mode of oncogenic activation of the Met receptor tyrosine kinase. Met is aberrantly activated in many types of human malignancies and its deregulated activity is correlated with aggressive tumor traits such as abnormal proliferation and survival, leading to tumor growth, local invasion and metastasis. Here we report that the Met kinase inhibitor SU11274 differentially affects the kinase activity and subsequent signaling of various mutant forms of Met. Two Met variants tested, M1268T and H1112Y, were potently inhibited by 2M SU11274, while two other variants, L1213V and Y1248H, remained resistant under similar experimental conditions. Inhibition of the kinase altered cell proliferation, morphology and motility, while cells containing resistant mutants appeared unaffected by the compound. The basis for the sensitivity or resistance to SU11274 is discussed in terms of the position of the mutations predicted from a homology model.
机译:点突变构成满足受体酪氨酸激酶的致癌活化的主要模式。遇见在许多类型的人类恶性肿瘤中被异常激活,其令人讨厌的活性与侵略性肿瘤特征相关,例如异常增殖和生存,导致肿瘤生长,局部侵袭和转移。在这里,我们认为Met激酶抑制剂SU11274差异地影响激酶活性和随后的各种突变形式的信号传导。测试的两个Met变体M1268T和H1112Y经常抑制2M SU11274,而另外两种变体L1213V和Y1248H在类似的实验条件下保持抗性。抑制激酶改变的细胞增殖,形态和动力,而含有抗性突变体的细胞出现不受该化合物的影响。就像来自同源模型预测的突变的位置而言,讨论了敏感性或抗性对SU11274的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号